DDrare: Database of Drug Development for Rare Diseases

Ns-304 placebo (DrugBank: -)

2 diseases

ID	Disease name (Link within this page)	Number of trials
70	Spinal stenosis	1
88	Chronic thromboembolic pulmonary hypertension	1

70. Spinal stenosis [ 91 clinical trials, 195 drugs, (DrugBank: 54 drugs), 60 drug target genes, 85 drug target pathways]

Searched query = "Spinal stenosis", "Extensive spinal canal stenosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 91 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JapicCTI-183866	02/2/2018	15/02/2018	Placebo-controlled, double-blind, exploratory study of NS-304 in lumbar spinal stenosis (LSS) patients with intermittent claudication (Early Phase II study)	Placebo-controlled, double-blind, exploratory study of NS-304 in lumbar spinal stenosis (LSS) patients with intermittent claudication (Early Phase II study)	LSS	Intervention name : NS-304 INN of the intervention : Selexipag Dosage And administration of the intervention : Oral administration Control intervention name : NS-304 Placebo INN of the control intervention : - Dosage And administration of the control intervention : Oral administration	Nippon Shinyaku Co., Ltd.	NULL	complete	40	79	BOTH	120	Phase 2	Japan

88. Chronic thromboembolic pulmonary hypertension [ 145 clinical trials, 112 drugs, (DrugBank: 22 drugs), 13 drug target genes, 52 drug target pathways]

Searched query = "Chronic thromboembolic pulmonary hypertension", "CTEPH", "Idiopathic chronic pulmonary thromboembolism"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 145 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JapicCTI-163279	10/6/2016	01/06/2016	A confirmatory (phase III) study of the efficacy and safety of NS-304 (selexipag) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)	A confirmatory (phase III) study of the efficacy and safety of NS-304 (selexipag) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)	Chronic thromboembolic pulmonary hypertension (CTEPH)	Intervention name : NS-304 INN of the intervention : Selexipag Dosage And administration of the intervention : Oral administration Control intervention name : NS-304 Placebo INN of the control intervention : - Dosage And administration of the control intervention : Oral administration	Nippon Shinyaku Co., Ltd.	NULL	complete	20	85	BOTH	72	Phase 3	Japan